MedTrace Logo

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

NCT04734106 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-27

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.

Conditions

  • Interstitial Cystitis
  • Chronic Interstitial Cystitis
  • Bladder Pain Syndrome

Interventions

DRUG

Desert Harvest Aloe Vera Capsules

600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.

OTHER

Placebo Capsules

550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.

Sponsors & Collaborators

  • Desert Harvest

    collaborator UNKNOWN

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Stephen Walker, PhD · Wake Forest Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2027-04-30
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734106 on ClinicalTrials.gov